Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results fromLate-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at th
Yahoo15 days agoCYTK
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
Yahoo15 days agoCYTK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of common stock and 18,273 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in July and August 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs ves
Yahoo16 days agoCYTK
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
Yahoo21 days agoCYTK
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.
Yahoo21 days agoCYTK
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
Benzinga22 days agoCYTK
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Benzinga22 days agoCYTK
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the
Benzinga22 days agoCYTK
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
Benzinga25 days agoCYTK
Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval
Cytokinetics stock has delivered strong multi year returns, yet its latest valuation checks point to a more mixed picture rather than a clear bargain or an obvious overvaluation. Cytokinetics has returned about 139% over the past 5 years, which puts extra focus on whether current holders are still being fairly compensated for the risks they are taking. The recent UK approval and reimbursement support for MYQORZO may support investor expectations for future revenue, while ongoing regulatory...
Yahoo27 days agoCYTK
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Yahoo28 days agoCYTK